Overall verdict
Sell
3.3/10
1-year performance
+1099.34%
Score breakdown
Up 1099.3% over 1 year, 97% of the 52-week range.
Strongest: Valuation 7.3/10. Weakest: Shareholder return 0.0/10.
Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer ;
and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Douglas Onsi
Founded
2011
Employees
6
Revenue / employee
0 USD
Next earnings
November 12, 2026 (estimated)
Institutional holders
- VANGUARD CAPITAL MANAGEMENT LLC4.03%
- BlackRock, Inc.2.72%
- JANE STREET GROUP, LLC1.76%
- GEODE CAPITAL MANAGEMENT, LLC1.22%
- UBS Group AG1.17%
- CITADEL ADVISORS LLC0.87%
- XTX Topco Ltd0.66%
- VANGUARD FIDUCIARY TRUST CO0.59%
- STATE STREET CORP0.53%
- Other institutions1.87%
- Rest of the register84.58%
46 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
4.14 USD
52-week low
0.31 USD
1-year performance
1099.34%
Rising
Year-to-date performance
219.47%
Rising
Drawdown
-2.66%
Near its high
Position in the 52-week range
97% of range
ROIC -1.2%, ROE -1.2%.
Net margin
—
Sector -15.60%|S&P 12.97%
Gross margin
—
Return on equity (ROE)
-1.21%
Negative
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
-1.21%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue up 0.0% over 1 year, -100.0% a year over 5.
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
0.00%
Declining
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
7.3/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
7.1x
Cheap
Sector 29.9x|S&P 23.0x
Forward P/E (adjusted)
14.4x
Cheap
EV / EBITDA
—
N/A (loss)
Sector 23.3x|S&P 14.5x
PEG
0.05
Growth unpriced
Sector 0.12|S&P 0.86
Market cap
389M USD
Financial strength
5.8/10Cash covers 20063.2% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-5.45%
Net cash
Cash
7.6M USD
Cash / market cap
1.96%
Stretched
Cash / total debt
20063.16%
Net cash
Interest coverage
-740.6x
Stretched
Net debt
-7.6M USD
Equity
139M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 4.08 USD
- MM202.59
- MM501.53
- MM2001.04
- RSI 1476.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+9.98%
200-day average slope, 3 months
+17.75%
50-day average slope, 1 month
+103.46%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
12.45 % per day
Volatility change
+32.18%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.04 (1) | -0.51 (1) | 42 (1) | — | -9 (1) |
| 2027 | 0.77 (1) | -0.09 (1) | 211 (1) | — | 186 (1) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 9, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.5 | 6.9 | 59.5Md USD | 36.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.9 % | 33.9 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | CYPH | 3.3 | 3.1 | 389M USD | 7.1x | — | 0.0 % | -1.2 % | — | -5.4 % | 1099.3 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
